In addition, the D3R-preferring D3R/D2R antagonist F17464 demonstrated therapeutic efficacy in improving the symptoms of acute exacerbation of schizophrenia with a favorable safety profile in a Phase II clinical trial [9]. This evidence concerns the gene DRD2 and schizophrenia.